Cara Therapeutics updates corporate presentation; cash $102M, pipeline catalysts outlined

Tvardi Therapeutics, Inc.

Cash position $102M as of June 30, 2023, no debt, cash runway at least 12 months.
KORSUVA injection launched in US (Apr 2022) and EU (Sep 2022); Japan approval expected 2H23.
Oral difelikefalin in phase 3 for advanced CKD (KICK1/2, topline 2H24) and atopic dermatitis (KIND1/2, topline 1H25).
Phase 2/3 for notalgia paresthetica (KOURAGE1) initiated 1Q23, topline 2H26.
Partner CSL Vifor handles commercialization; Cara has no cash outlay for commercial costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.